RPG Life Sciences Ltd management interview: RPG Life Sciences Reports Mixed Q2FY27 Performance | CNBC TV18
CNBC-TV18, 2026-10-30. Video: https://www.youtube.com/watch?v=IRHVdUMn8vA
- Q2 milestones: RPG Life Sciences crossed ₹200 crore in quarterly revenue, growing 16.5%, and delivered its first ₹50 crore EBITDA quarter, with adjusted EBITDA growing 15%. Gross margins expanded by 260 basis points, and volumes grew by 6.8%.
- Profit and margins: Management said operational margins were not under pressure; PBT grew by 11% in Q2, while apparent moderation in reported profit should be viewed against exceptional income recognised in quarter 2 of FY26. Excluding the one-time acquisition cost of around ₹6 crores, PBT recorded healthy growth.
- Oncology price caps: The company welcomed the government’s move, saying its selling price remains broadly unchanged while MRP falls as trade markups are capped. It expects no material impact on sales or margins and said improved affordability could support patient access and volumes.
- API growth plans: With the plant back in operation and new customers and markets, management expects double-digit growth. After forming RPG ActiPharma, bringing in Invest India as a strategic partner and completing the ACTIS and RAGVA acquisitions, it is targeting a 25% CAGR and is seeking another asset in the next 12 months, using a ₹500 crore pool.